Theyll evaluate factors like dialysis schedules, remaining kidney function, and current medications to create a safe and effective plan
BPC-157 at PCAC: The First Chapter in a Larger Regulatory Debate Todays PCAC review of BPC-157 is only the first phase of a broader process
Medications highlighted in the graphic include: Oral Wegovy - GLP-1 receptor agonist - ~13 to 17% estimated weight loss Wegovy 7.2 mg - Higher-dose injectable GLP-1 - ~20 to 21% estimated weight loss Orforglipron - Oral non-peptide GLP-1 agonist - ~11 to 15% estimated weight loss CagriSema - Amylin analog + GLP-1 agonist - ~20 to 23% estimated weight loss Retatrutide - Triple agonist (GIP, GLP-1, glucagon) - up to ~28 to 29% estimated weight loss Survodutide - Dual agonist (GLP-1, glucagon) - ~15 to 19% estimated weight loss MariTide - GIP antagonist + GLP-1 antibody-drug conjugate - ~18 to 20% estimated weight loss A few important notes for context: The percentages shown are trial-based estimates and vary by dose, duration, and analysis method Timelines reflect best estimates, not guarantees Real-world outcomes will depend on access, tolerability, and individualized care That said, the direction is clear
There is a dearth of clinical data in humans, so any use should be cautious and supervised where legal
